Hours

Minutes

Seconds

-40%

on all subscriptions*

Last days

Enjoy this offer

* See conditions under "Our services"

Valuation: AP Biosciences, Inc.

Market Cap	8.77B 277M 240M 221M 207M 387M 26.37B 393M 2.61B 1.02B 12.83B 1.04B 1.02B 44.44B	P/E Ratio 2024	-8.86x	P/E Ratio 2025	-34.4x
Enterprise Value	7.66B 242M 209M 193M 180M 338M 23.03B 343M 2.28B 888M 11.21B 909M 890M 38.8B	EV / Sales 2024	-	EV / Sales 2025	-
Free-Float	41.89%	Yield 2024 *	-	Yield 2025	-

* Estimated data More valuation ratios

Latest news : AP Biosciences, Inc.

05-14	AP Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
05-12	Delos Capital and AP Biosciences Inc. Launch Collaboration to Create New Biotech Companies Focused on Next-Generation Antibodies	CI
03-31	AP Biosciences, Inc. has filed an IPO in the amount of TWD 1.2562 billion.	CI
03-22	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
12-21	AP Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
25-08-12	AP Biosciences, Inc. Reports Earnings Results for the Half Year Ended June 30, 2025	CI
25-05-13	AP Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024	CI
25-04-29	AP Biosciences Presents Preclinical Data on P95her/Cd137 T-Cell Engager At American Association of Cancer Research Annual Meeting	CI
25-04-22	AP Biosciences Doses First Patient In Phase 1/2 Clinical Trials Of AP402 For HER2+ Cancer Patients	RE
25-04-22	AP Biosciences Doses First Patient in Phase 1/2 Clinical Trials of AP402 for HER2+ Cancer Patients	CI
25-04-21	AP Biosciences to Present New Preclinical Data at American Association of Cancer Research Annual Meeting	CI
24-08-12	AP Biosciences Inc Reports Earnings Results for the Half Year Ended June 30, 2024	CI
24-03-19	AP Biosciences Inc Reports Earnings Results for the Full Year Ended December 31, 2023	CI

More news

Press Releases: AP Biosciences, Inc.

25-07-24

Designing antibodies to think before they bind

More press releases

Managers and Directors: AP Biosciences, Inc.

Manager	Title	Age	Since
Jeng-Horng Her CEO	Chief Executive Officer	-	2013-05-26
Shu Cheng Lin DFI	Director of Finance/CFO	-	2022-10-17
Wan Ju Tseng ADM	Chief Administrative Officer	-	2022-10-17

Director	Title	Age	Since
Chih Chuan Chen CHM	Chairman	-	2023-05-22
Jeng-Horng Her BRD	Director/Board Member	-	2022-11-08
Shih Ming Lin BRD	Director/Board Member	-	2023-05-22

More insiders

AP Biosciences Inc is a Taiwan-based company mainly engaged in the research and development of protein drugs and antibody drugs. The Company develops early candidate drugs and preclinical trials, and develops different monoclonal or bispecific antibody drugs for potential targets, mechanisms of action, and disease characteristics through drug design and existing technology platforms. The Company's technology platform and bispecific protein drug research and development projects include IBI302-anti-vascular endothelial growth factor (VEGF) and anti-complement bifunctional recombinant protein, OmniMab fully human antibody library, AP505-PD-L1 x VEGF bispecific antibody, target-directed T cell activation 3T platform (T-cube), AP203-PD-L1 x CD137 fully human bispecific antibody, and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Quotes

Date	Price	Change	Volume
26-06-14	102.50 NT$	+2.60%	366,538
26-06-12	99.90 NT$	-0.10%	333,555
26-06-11	100.00 NT$	-1.96%	314,946
26-06-10	102.00 NT$	0.00%	332,001
26-06-09	102.00 NT$	-1.92%	281,852

End-of-day quote Taipei Exchange

More quotes

Income Statement and Estimates

More financial data

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

United-States

Canada

End-of-day quote Taipei Exchange Other stock markets 2026-06-15			5-day change	1st Jan Change
102.50 ^TWD	+2.60%		-2.38%	-43.06%

1 day	+2.60%
1 week	-2.38%
Current month	-18.33%
1 month	-42.25%
3 months	-41.09%
6 months	-43.21%
Current year	-43.06%

1 week	97.8	104.5
1 month	97.1	182
Current year	97.1	236
1 year	52.3	236
3 years	36.3	236
5 years	36.3	236
10 years	36.3	236

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
AP BIOSCIENCES, INC.	+2.60%	-2.38%	+90.17%	-	270M
ARGENX SE	-2.86%	-0.26%	+57.57%	+110.98%	56.42B
WUXI APPTEC CO., LTD.	-0.34%	+2.91%	+45.55%	+46.87%	44.54B
BIONTECH SE	+1.23%	+7.32%	-13.70%	-18.80%	22.9B
INSMED INCORPORATED	+1.01%	+5.13%	-2.54%	+394.78%	21.21B
WUXI BIOLOGICS (CAYMAN) INC.	-0.51%	-5.56%	+10.43%	-29.97%	16.4B
GENMAB A/S	-1.54%	-1.06%	+8.10%	-39.28%	15.4B
EXELIXIS, INC.	-0.34%	+1.95%	+26.35%	+176.18%	13.35B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	+0.96%	+6.56%	+20.81%	-	12.36B
PHARMAESSENTIA CORPORATION	+0.32%	+1.60%	+96.37%	+207.56%	11.15B
Average	+0.06%	+1.54%	+33.91%	+106.04%	21.4B
Weighted average by Cap.	-0.68%	+2.54%	+32.30%	+98.64%

	2024	2025
Net sales	-	-
Net income	-423M -13.37M -11.55M -10.64M -9.96M -18.67M -1.27B -18.95M -126M -48.99M -619M -50.17M -49.11M -2.14B	-445M -14.07M -12.15M -11.19M -10.48M -19.64M -1.34B -19.94M -132M -51.54M -651M -52.79M -51.66M -2.25B
Net Debt	-1.47B -46.51M -40.17M -37.02M -34.65M -64.94M -4.42B -65.94M -437M -170M -2.15B -175M -171M -7.45B	-1.11B -35.15M -30.36M -27.97M -26.18M -49.07M -3.34B -49.83M -330M -129M -1.63B -132M -129M -5.63B

AP Biosciences, Inc. Stock

Stocks

6945

TW0006945009

Biotechnology & Medical Research

Valuation: AP Biosciences, Inc.

Chart: AP Biosciences, Inc.

Latest news : AP Biosciences, Inc.

Press Releases: AP Biosciences, Inc.

Quotes and Performance

Course Extremes

Managers and Directors: AP Biosciences, Inc.

Bio Therapeutic Drugs

Financials

Company Profile

Quotes

Income Statement and Estimates